Conservative treatment of 83 patients with subtotal central retinal artery occlusion
| Pentoxifyllin Infusions | Hemodilution | Aspirin | Acetacolamide (Diamox) | Rheomacrodex Infusions | Heparin | Eye Drops for Lowering Eye Pressure | Paracentesis |
|---|---|---|---|---|---|---|---|
| 29 (34.9%) | 46 (54.21%) | 28 + 1 Plavix + 1 Tiklyd: 30 (36.14%) | 9 (10.84%) | 8 (9.64%) | 16 (19.28%) | 11 (13.25%) | 13 (15.66%) |
| Additional treatment or single treatment | |||||||
| Pentoxifyllin + additional treatment*: 21 patients (25.3%) | Pentoxifyllin + additional treatment†: 36 (43.37%) | Aspirin + additional treatment‡: 25 (30.12%) | Acetacolamide + additional treatment§: nine (10.84%) | Rheomacrodex + additional treatment§§: eight (9.64%) | Heparin + additional treatment: 14 (16.87%) | Eye drops + additional treatment: 11 (13.25%) | Paracentesis + additional treatment: 11 (13.25%) |
| Pentoxifyllin only: eight patients (9.64%) | Hemodilution only: 10 (12.05%) | Aspirin only: five (6.02%) | Acetacolamide only | Rheomacrodex only | Heparin only: two (2.41%) | Eye drops only | Paracentesis only: two (2.41%) |
Note.—In all patients, immediate massage of the globe and treatment of high blood pressure were performed.
* Pentoxifyllin + aspirin, five (6.02%) patients; Pentoxifyllin + Diamox, one (1.2%) patient; Pentoxifyllin + aspirin + Diamox, one patient; Pentoxifyllin + Rheomacrodex, two (2.41%) patients; Pentoxifyllin + hemodilution, one patient; Pentoxifyllin + Paracentesis, three (3.61%) patients; Pentoxifyllin + hemodilution + aspirin + paracentesis, one patient; Pentoxifyllin + eye drops + paracentesis, two (2.41%) patients; Pentoxifyllin + hemodilution + eye drops + paracentesis, one patient; Pentoxifyllin + hemodilution + aspirin + heparin: one patient; Pentoxifyllin + Diamox + Rheomacrodex + paracentesis, one patient; Pentoxifyllin + hemodilution + eye drops, one patient; Pentoxifyllin + Diamox + paracentesis, one patient.
† Hemodilution + aspirin, 12 (14.45%) patients; hemodilution + eye drops, three (3.61%) patients; hemodilution + heparin, 10 (12.05%) patients; hemodilution + aspirin + heparin, one (1.2%) patient; hemodilution + aspirin + eye drops, one patient; hemodilution + Diamox + Rheomacrodex + paracentesis, one patient; hemodilution + aspirin + Diamox + heparin, one patient; hemodilution + eye drops + Diamox, one (1.2%) patient.
‡ Aspirin + Heparin, one patient; aspirin + Rheomacrodex, one patient.
§ Diamox + Rheomacrodex + eye drops, two patients.
§§ Rheomacrodex + paracentesis, one patient.